---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-010668"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2026-02-05T23:59:59+00:00"
generated_at: "2026-05-16T04:32:03.352800+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TransCode submits IND amendment for Phase 2a trial of TTX-MC138 in colorectal cancer

## Summary
- IND amendment filed with FDA for Phase 2a dose-expansion trial of TTX-MC138 in colorectal cancer patients with ctDNA-positive MRD.
- Trial to enroll up to 45 patients who completed curative-intent therapy; expected start in first half 2026.
- Study conducted by Quantum Leap Healthcare within PRE-I-SPY platform, its first expansion into colorectal cancer.
- Principal Investigator Dr. Paula Pohlmann of MD Anderson Cancer Center leads the trial.
- Collaboration with Quantum Leap and support from Colorectal Cancer Alliance; trial ID NCT05868226.

## SEC filing metadata
- accession: 0001104659-26-010668
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2026-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465926010668/0001104659-26-010668-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465926010668/tm265309d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-010668
- JSON: https://secwatch.observer/filing/0001104659-26-010668.json
- Plain text: https://secwatch.observer/filing/0001104659-26-010668.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.